Why The US Pays More For The Same Medications Than Everyone Else with Dr. Jerry Avorn
Turn on the Lights PodcastShow Notes
America’s drug crisis isn’t a science problem; it’s a pricing and policy problem that blocks patients from medicines that already exist.
In this episode, Dr. Jerry Avorn, a professor of medicine and leading expert in pharmacoepidemiology and medication policy, discusses why many patients still can’t afford essential treatments even as breakthrough drugs for cancer and inflammatory disease proliferate. He shares a personal case where “nonadherence” was really unaffordability, then unpacks how US exceptionalism in drug pricing, patent “thickets,” and delayed competition keep costs unsustainably high. Dr. Avorn also contrasts access failures with overuse concerns, explores why other countries negotiate on the basis of value, and addresses objections to innovation and rationing, including a sobering example of cystic fibrosis in the UK. Finally, he explains how academic detailing spreads evidence-based prescribing and evaluates recent US attempts to let Medicare negotiate prices alongside more deal-driven approaches.
Tune in and learn how drug prices, patents, and public funding shape what patients can actually access!
Resources:
Connect with and follow Dr. Jerry Avorn on LinkedIn.
Follow Harvard Medical School on LinkedIn and explore their website!
Learn more about Brigham and Women’s Hospital on LinkedIn and visit their website.
Visit Dr. Avorn’s personal website.
Buy the Rethinking Meds book here and learn more about it here.
More from Turn on the Lights Podcast
AI is rapidly transforming how people access health information, but its greatest value will depend on whether it strengthens, rather than replaces, trust, equity, and human connection.
What would it take for AI to make health care more accessible without making it less human?
What happens when false narratives about Latino communities become a public health threat?
What would change if healthcare listened more deeply to Black breast cancer survivors and built systems around their experiences, expertise, and lives?
What would change if health care truly organized itself around what matters most to older adults, patients, families, and caregivers?